ONECUT2 and colorectal carcinoma: Studies have shown that TRMT61A promotes cancer in CRC by activating the m1A-ONECUT2-SOS1-MAPK/ERK pathway [217], suggesting that targeting TRMT61A may offer a viable therapeutic strategy for CRC.